ACRUX Ltd Asset Resilience Ratio
ACRUX Ltd asset resilience ratio. ACRUX Ltd (ACR) has an Asset Resilience Ratio of 11.94% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ACR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ACRUX Ltd (2016–2023)
Asset resilience ratio of ACRUX Ltd from 2016 to 2023. This chart shows how ACRUX Ltd's Asset Resilience Ratio has changed over time. Read ACRUX Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ACRUX Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ACR total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$863.00K | 11.94% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$863.00K | 11.94% |
Asset Resilience Insights
- Moderate Liquidity: ACRUX Ltd has 11.94% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
ACRUX Ltd Industry Peers by Asset Resilience Ratio
Compare ACRUX Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
ACRUX Ltd Asset Resilience Ratio by Year (2016–2023)
ACRUX Ltd asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for ACRUX Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 20.98% | AU$3.00 Million ≈ $2.12 Million |
AU$14.30 Million ≈ $10.12 Million |
+1.34pp |
| 2022-06-30 | 19.64% | AU$3.00 Million ≈ $2.12 Million |
AU$15.27 Million ≈ $10.81 Million |
-13.41pp |
| 2021-06-30 | 33.06% | AU$8.00 Million ≈ $5.66 Million |
AU$24.20 Million ≈ $17.12 Million |
-10.14pp |
| 2020-06-30 | 43.19% | AU$8.00 Million ≈ $5.66 Million |
AU$18.52 Million ≈ $13.10 Million |
-30.48pp |
| 2019-06-30 | 73.67% | AU$18.00 Million ≈ $12.74 Million |
AU$24.43 Million ≈ $17.29 Million |
-11.28pp |
| 2018-06-30 | 84.95% | AU$27.60 Million ≈ $19.53 Million |
AU$32.49 Million ≈ $22.99 Million |
+34.54pp |
| 2017-06-30 | 50.41% | AU$23.85 Million ≈ $16.87 Million |
AU$47.31 Million ≈ $33.47 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$53.37 Million ≈ $37.76 Million |
-- |
About ACRUX Ltd
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for th… Read more